The Clinically Studied Oral Supplement for Brighter, Clearer Skin

Crystal Tomato® Whitening Supplement was evaluated in a double-blind, randomised, placebo-controlled clinical trial - a rigorous study design intended to reduce bias. The study was conducted at the National Skin Centre, Singapore, and its results were published in the peer-reviewed U.S. Journal of Pigmentary Disorders. This page summarises what the researchers measured, what they found, and what those findings mean for your skin.

The Study at a Glance

In a double-blind, randomised, placebo-controlled trial, neither the participants nor the researchers knew who received the active supplement and who received a placebo until the study was complete - a rigorous study design intended to reduce bias when evaluating efficacy. The trial enrolled 44 participants with melasma, of whom 36 completed all three study visits. Assessments were conducted at baseline, Week 8, and Week 12. All 44 enrolled participants were included in the analysis. Pigmentation was measured using the modified Melasma Area and Severity Index (mMASI), a validated clinical scoring system, and skin redness was assessed using an erythema score.

By Week 12, 53% of participants in the Crystal Tomato® group achieved more than a 50% improvement in melasma severity (mMASI score), compared with 31.6% in the placebo group.

What this means: This is a responder measure: it reports how many people achieved a substantial result, not an average across the group. More than half the active group achieved over 50% improvement in pigmentation severity, at roughly 1.7× the rate seen on placebo. The placebo group followed the same sun-avoidance and skincare regimen.

• Participants receiving Crystal Tomato® together with a topical lightening regimen showed a 46% reduction in melasma severity (mMASI score) by Day 54, compared with placebo.

No adverse effects attributed to the Whitening Supplement were reported during the clinical study. These findings provide safety and tolerability data for the oral supplement over the 12-week study period.

Crystal Tomato® is formulated with colourless carotenoid-rich tomato powder from non-GMO tomatoes, together with L-cysteine. Unlike carotenoids such as carotene and lycopene, which contribute yellow, orange and red colour, colourless carotenoids such as phytoene and phytofluene primarily absorb in the ultraviolet rather than the visible region of the spectrum and are therefore essentially colourless. The formulation used in the trial provided 800 mg of colourless carotenoid-rich tomato powder and 50 mg of L-cysteine per caplet. L-cysteine supports the body's production of glutathione, an antioxidant.

This double-blind, randomised, placebo-controlled clinical trial was conducted at the National Skin Centre, Singapore, and published in the U.S. Journal of Pigmentary Disorders. Crystal Tomato® is independently formulated; references to the institution describe where the study took place and do not imply endorsement. Results may vary depending on individual skin type and usage.